Advertisement
Advertisement
ENSC
Ensysce Biosciences, Inc. Common Stock
0.43
USDSponsored
-0.09
-17.24%
Aug 10, 15:59 UTC -4
Closed
After-Market
0.40
-0.03
-7.78%
ENSC Earnings Reports
Positive Surprise Ratio
ENSC beat 13 of 18 last estimates.
72%
Next Report
Tomorrow
Date of Next Report
Aug 11, 2026
Estimate for Q2 26 (Revenue/ EPS)
$1.94M
/-$0.51
Implied change from Q1 26 (Revenue/ EPS)
+101.66%
/-1.92%
Implied change from Q2 25 (Revenue/ EPS)
+41.36%
/-35.44%
Ensysce Biosciences, Inc. Common Stock earnings per share and revenue
On May 15, 2026, ENSC reported earnings of -0.52 USD per share (EPS) for Q1 26, beating the estimate of -0.74 USD, resulting in a 30.16% surprise. Revenue reached 961.00 thousand, compared to an expected 1.94 million, with a -50.41% difference. The market reacted with a +13.17% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 3 analysts forecast an EPS of -0.51 USD, with revenue projected to reach 1.94 million USD, implying an decrease of -1.92% EPS, and increase of 101.66% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bionano Genomics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.69
Actual
-$0.64
Surprise
+8.40%
Biohaven Ltd.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.74
Actual
-$0.91
Surprise
-21.67%
Alamar Biosciences, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.22
Surprise
+33.83%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.55
Actual
-$0.61
Surprise
-9.83%
Enanta Pharmaceuticals, Inc
Report Date
Aug 10, 2026 For Q3 26
Estimate
-$0.52
Actual
-$0.67
Surprise
-28.80%
Rocket Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
$0.24
Actual
-$0.15
Surprise
-160.80%
Palisade Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.05
Surprise
+6.19%
DiaMedica Therapeutics Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.19
Surprise
+6.86%
Orchestra BioMed Holdings, Inc. Ordinary Shares
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.38
Surprise
+4.95%
Nkarta, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.54
Surprise
-40.81%
FAQ
What were Ensysce Biosciences, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Ensysce Biosciences, Inc. Common Stock reported EPS of -$0.52, beating estimates by 30.16%, and revenue of $961.00K, -50.41% below expectations.
How did the market react to Ensysce Biosciences, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 13.17%, changed from $0.28 before the earnings release to $0.32 the day after.
When is Ensysce Biosciences, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 11, 2026.
What are the forecasts for Ensysce Biosciences, Inc. Common Stock's next earnings report?
Based on 3
analysts, Ensysce Biosciences, Inc. Common Stock is expected to report EPS of -$0.51 and revenue of $1.94M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement